Low Vision Aid Device for Farsightedness
(Opti-K Pres Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new device called the VIS Opti-K Low Vision Aid, designed to improve vision for people with farsightedness. It targets individuals who have difficulty seeing up close, such as when reading, and experience mild trouble seeing far away. Ideal participants do not wear contacts, have good overall eye health, and require glasses for reading. The trial aims to determine if this device can improve their sight without the need for glasses. As an unphased trial, it offers participants the chance to potentially enhance their vision with an innovative device.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinator or your doctor.
What prior data suggests that this device is safe for vision improvement?
Earlier studies have used the VIS Opti-K Low Vision Aid device to assist individuals with vision issues like presbyopia (difficulty seeing things up close with age) and hyperopia (farsightedness). These studies have evaluated the device's safety and effectiveness in improving vision.
The VIS Opti-K device is noninvasive, meaning it doesn't involve surgery, which typically results in fewer risks and side effects compared to surgical treatments. Initial results from other studies suggest that most people tolerate the device well. Some mild side effects have been reported, but they are uncommon.
This trial is in the "Not Applicable" phase, indicating that the device is still under study for wider use, though it has already passed some safety checks. Always discuss any concerns with a doctor before joining a trial.12345Why are researchers excited about this trial?
The VIS Opti-K Low Vision Aid Device is unique because it offers a non-invasive solution for farsightedness, unlike traditional options like glasses or contact lenses. This device is designed to enhance vision through advanced optics, potentially providing a more seamless experience for users compared to conventional corrective lenses. Researchers are excited about this treatment because it could offer an immediate improvement in vision without the need for surgical intervention or ongoing maintenance associated with other vision correction methods.
What evidence suggests that the VIS Opti-K Low Vision Aid Device is effective for vision improvement in farsightedness?
Research shows that the VIS Opti-K Low Vision Aid device, used by participants in this trial, may improve vision for those who are farsighted or have difficulty seeing up close due to aging. Studies have found that the device can enhance clarity by temporarily adjusting eye focus. This occurs through optimal keratoplasty, a method that reshapes the cornea to improve vision. Early results indicate that many users notice clearer vision for nearby objects. Although further research is necessary, these initial findings offer promise for those seeking non-surgical vision improvement.14678
Who Is on the Research Team?
Michael Berry, PhD
Principal Investigator
VIS, Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 40 with presbyopia or farsightedness, who have a certain level of uncorrected and corrected visual acuity, need reading glasses of +1.0 to +3.0 D, and have normal corneal topography without significant cataracts. It's not for those with diabetes, glaucoma, high eye pressure, pregnancy, nystagmus (rapid eye movement), any corneal disease or past eye surgeries.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the VIS Opti-K Low Vision Aid device for vision improvement
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VIS Opti-K Low Vision Aid Device
Find a Clinic Near You
Who Is Running the Clinical Trial?
VIS, Inc.
Lead Sponsor